Matinas biopharma reports second quarter 2022 financial results and highlights recent progress

75% of patients enrolled to date in cohort 4 of enact (mat2203 in cryptococcal meningitis); topline data in late q3/early q4 2022
MTNB Ratings Summary
MTNB Quant Ranking